Biogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed National Coverage Determination (NCD) for Anti-Amyloid Treatments in Alzheimer’s Disease
Biogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed National Coverage Determination (NCD) for Anti-Amyloid Treatments in Alzheimer’s Disease
February 10, 2022
• Company Statements
October 3, 2022
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2 LRRK2 mutations are one of the most common genetic drivers of Parkinson’s disease Targeting LRRK2 has the potential to impact the underlying biology and slow the progression of Parkinson’s disease
September 30, 2022
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA ®1 (tocilizumab), an anti-interleukin-6 receptor